Psychological Effects of 8 Weeks Supplementation With Sceletium Tortuosum Extract (ZEMBRIN)
Psychological Effects of 8 Weeks Supplementation With Sceletium Tortuosum Extract (Zembrin™): a Randomised, Double Blind, Placebo-controlled, Parallel-groups Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Emma Wightman, PhD
- Phone Number: 7252 +44(0)191 234
- Email: emma.l.wightman@northumbria.ac.uk
Study Contact Backup
- Name: David Kennedy, Professor
- Email: david.kennedy@northumbria.ac.uk
Study Locations
-
-
Tyne And Wear
-
Newcastle Upon Tyne, Tyne And Wear, United Kingdom, NE1 8ST
- Recruiting
- Brain Performance and Nutrition Research Centre
-
Contact:
- Emma Wightman, Dr
- Phone Number: 0191 227 3725
- Email: emma.l.wightman@northumbria.ac.uk
-
Contact:
- David Kennedy, Professor
- Phone Number: 0191 243 7720
- Email: david.kennedy@northumbria.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Participants must self-assess themselves as being in good health Aged 30 to 50 years at the time of giving consent
Exclusion Criteria:
Participants are not eligible to take part if they:
- Have any pre-existing medical condition/illness which will impact taking part in the study NOTE: the explicit exceptions to this are controlled hay fever, high cholesterol and reflux-related conditions. There may be other, unforeseen, exceptions and these will be considered on a case-by-case basis; i.e. participants may be allowed to progress to screening if they have a condition/illness which would not interact with the active treatments or impede performance.
- Are currently taking prescription medications NOTE: the explicit exceptions to this are contraceptive treatments for female participants, those medications used in the treatment of reflux-related conditions; and those taken 'as needed' in the treatment of asthma and hay fever. As above, there may be other instances of medication use which, where no interaction with the active treatments is likely, and which would not be expected to have any impact on brain function, participants may be able to progress to screening.
- Have high blood pressure (systolic over 159 mm Hg or diastolic over 99 mm Hg)
- Have a Body Mass Index (BMI) outside of the range 18.5-35 kg/m2
- Are pregnant, seeking to become pregnant or lactating.
- Are menopausal/post-menopausal
- Have learning and/or behavioural difficulties such as dyslexia or ADHD
- Have a visual impairment that cannot be corrected with glasses or contact lenses (including colour-blindness)
- Smoke tobacco or vape nicotine or use nicotine replacement products
- Take any illicit social drugs, including cannabis
- Have excessive caffeine intake (>500 mg per day)
- Have relevant food intolerances/ sensitivities
- Have taken antibiotics within the past 4 weeks
- Have taken dietary supplements eg. Vitamins, omega 3 fish oils, herbal extracts, cannabadiol etc. in the last 4 weeks (Note: participation is possible following a 4 week supplement washout prior to participating and for the duration of the study on the proviso that the supplements they are taken are out of choice and not medically prescribed or advised). Existing and consistent use of vitamin D supplements and protein shakes are permitted
- Have any health condition that would prevent fulfilment of the study requirements (this includes non-diagnosed conditions for which no medication may be taken)
- Are unable to complete all of the study assessments
- Are currently participating in other clinical or nutrition intervention studies, or have in the past 4 weeks
- Has been diagnosed with/ undergoing treatment for alcohol or drug abuse in the last 12 months
- Have been diagnosed with/ undergoing treatment for a psychiatric disorder in the last 12 months
- Suffers from frequent migraines that require medication (more than or equal to 1 per month)
- Sleep disorders or are taking sleep aid medication
- Any known active infections
- Have oral disease
- Does not have a bank account (required for payment)
- Are non-compliant with regards treatment consumption
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo control
An inert tablet with the same physical appearance as the experimental intervention tablet
|
Zembrin® is a proprietary low-alkaloid extract of Sceletium tortuosum, often consumed by healthy humans in order to decrease anxiety and stress and improve cognitive function under stressful situations
Other Names:
|
|
Experimental: Zembrin
25 mg per day of Sceletium tortuosum extract (Zembrin®)
|
Zembrin® is a proprietary low-alkaloid extract of Sceletium tortuosum, often consumed by healthy humans in order to decrease anxiety and stress and improve cognitive function under stressful situations
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subjective stress
Time Frame: 56 days
|
This outcome will be assessed via changes on the Perceived Stress Scale (PSS).
This is a 10 item scale scored from 0 (NEVER) to 4 (very often) with a higher score indicating greater stress.
|
56 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mental fatigue
Time Frame: 56 days
|
This outcome will be assessed via changes on the Multidimensional Fatigue Inventory (MFI-20).
This is a 20 item questionnaire scored from 1 (yes, that is true) to 7 (no, that is not true) with higher scores indicating more fatigue.
|
56 days
|
|
Subjective happiness
Time Frame: 56 days
|
This outcome will be assessed via changes on the Oxford Happiness Questionnaire (OHQ).
This is a 29 item questionnaire scored from 1 (strongly disagree) to 6 (strongly agree) with a higher score indicating greater happiness.
|
56 days
|
|
Subjective alertness
Time Frame: 56 days
|
This outcome will be assessed via changes on the Visual Analogue Scale (VAS) for alertness.
This VAS is a 100 mm line with 'not alert' and 'alert' anchoring each end of the line.
This is scored from mm distance along the line towards 'alert'; with a higher score indicating greater alertness.
|
56 days
|
|
Physical fatigue/ sleep quality
Time Frame: 56 days
|
This outcome will be assessed via changes on the Athens Insomnia Scale (within the MFI-20).
This is scored as per the MFI detailed in outcome 2 above.
|
56 days
|
|
Cognitive function
Time Frame: 56 days
|
This outcome will be assessed via changes on the cognitive task outcomes (measured via COMPASS).
COMPASS is a proprietorial software platform for delivering a range of cognitive tasks; assessing domains like memory and attention, with tasks scored for accuracy (% correct) and speed (msec).
|
56 days
|
|
Physiological induced stress
Time Frame: 56 days
|
This outcome will be assessed via changes in heart rate (beats per minute) during the observed multitasking stressor.
Higher values indicate greater stress.
|
56 days
|
|
Psychological induced stress
Time Frame: 56 days
|
This outcome will be assessed via changes on the State portion Trait Anxiety Inventory (STAI).
The state portion of this questionnaire comprises 20 items which is scored from 1 (not at all) to 4 (very much so) with a higher score indicating greater stress.
|
56 days
|
|
Galvanic skin response
Time Frame: 56 days
|
This outcome will be assessed via changes in galvanic skin response (micro siemans) during the observed multitasking stressor).
Higher values indicate greater stress.
|
56 days
|
|
Salivary cortisol
Time Frame: 56 days
|
This outcome will be assessed via changes in salivary cortisol (nmol/L) during the observed multitasking stressor.
Higher values indicate greater stress.
|
56 days
|
|
Alpha Amylase
Time Frame: 56 days
|
This outcome will be assessed via changes in alpha amylase (nmol/L) during the observed multitasking stressor.
Higher values indicate greater stress.
|
56 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Emma Wightman, PhD, Northumbria University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 61CC1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.